secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0000950170-25-046064
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences reports $86.5M net loss for 2024; cash runway through 2027; three INDs cleared
--------------------------------------------------------------------------------

- Cash, equivalents, and marketable securities $341.4M at YE 2024 (up from $203.5M), providing runway through at least 2027.
- Full-year 2024 net loss $86.5M vs $69.1M in 2023; R&D expenses $80.1M vs $62.5M.
- TYRA-300 showed 54.5% confirmed PR (6/11) at ≥90mg QD in FGFR3+ mUC patients (SURF301).
- Three INDs cleared: TYRA-300 Phase 2 for NMIBC (SURF302) and ACH (BEACH301), and TYRA-430 Phase 1 (SURF431).
- First patient dosing expected Q2 2025 for BEACH301 (achondroplasia), SURF302 (NMIBC), and SURF431 (HCC).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000095017025046064/0000950170-25-046064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000095017025046064/tyra-20250327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-046064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer